John P. Sfakianos, MD, discusses the significance of urine-based biomarkers for intermediate-risk patients and outlines key findings from the STRATA study.
John P. Sfakianos, MD
Advertisement
Articles by John P. Sfakianos, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5
